Skip to main content

Remote Job Finders (RJF)

FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum

Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.

Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues

Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
Scroll to top